Gary Charles Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), reported an insider sell on August 28, according to a new SEC filing. What Happened: Robb’s recent move involves selling 3,101 shares of Corcept Therapeutics. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value is $110,736. During Thursday’s morning session, Corcept Therapeutics shares down by 0.0%, currently priced at $34.44. Discovering Corcept Therapeutics: A Closer LookCorcept Therapeutics Inc is a commercial-stage pharmaceutical comp…